 The FDA has signed off BioVie Incs NASDAQ: BIVI Phase 2 study assessing NE3107s potential pro-motoric impact in Parkinsons disease patients. The NM201 study is a double-blind, placebo-controlled, safety, tolerability, and pharmacokinetics study in Parkinsons disease PD participants treated with carbidopalevodopa and NE3107. 